Business Plans, Clinical Trial Results, Meetings, Conferences, and Sponsorships - Analyst Notes on Baxter, Halozyme, WellCare, PDL BioPharma, and Lannett

NEW YORK, April 1, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), WellCare Health Plans, Inc. (NYSE: WCG), PDL BioPharma, Inc. (NASDAQ: PDLI), and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Baxter International Inc. Analyst Notes 

On March 27, 2014, Baxter International Inc. (Baxter) announced its plans to create two separate, independent global healthcare companies. According to Baxter, one company will be focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Robert L. Parkinson, Jr., Chairman and CEO, commented, "Baxter has an established history of executing successful spinoffs, and we have continued to evaluate the separation of these two businesses in response to diverging business dynamics and the rapidly changing macro-environment. This decision underscores Baxter's commitment to ensuring its long-term strategic priorities remain aligned with shareholders' best interests, while improving our competitive position and performance, enhancing operational, commercial and scientific effectiveness and creating value for patients, healthcare providers, and other key stakeholders." The full analyst notes on Baxter International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/BAX/report.pdf

--

Halozyme Therapeutics, Inc. Analyst Notes 

On March 25, 2014, Halozyme Therapeutics, Inc. (Halozyme) announced positive results from Phase 1/2 clinical trial, evaluating the use of HTI-501 in the treatment of cellulite. Halozyme stated that the primary endpoint of the clinical trial was met and showed a statistically significant improvement in the appearance of cellulite in the areas of the patients' skin treated with HTI-501. The Company added that in follow up, the effect was maintained at three and six months, as assessed by the physician. Commenting on the results, Francisco Perez, M.D., former President of World Congress of Cosmetic Dermatology and Principal Clinical Investigator for the study, stated, "We are very pleased that this study has shown successful proof of concept of the activity of this novel enzyme. These data support further development of HTI-501 as a potential treatment for cellulite, a highly prevalent condition with very limited therapeutic options." The full analyst notes on Halozyme Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/HALO/report.pdf

--

WellCare Health Plans, Inc. Analyst Notes 

On March 25, 2014, WellCare Health Plans, Inc. (WellCare) and the Southwest Florida region of the American Diabetes Association (ADA) announced that the Company's WellCare Community Foundation will serve as the Presenting Sponsor of Tampa Bay's 2014 "Step Out: Walk to Stop Diabetes," to be held on October 18, 2014 in downtown Tampa, Florida. Dr. Steven Goldberg, Senior Vice President and Chief Medical Officer of WellCare, stated, "We are proud and pleased to be the Presenting Sponsor of this year's Step Out: Walk to Stop Diabetes. A significant portion of WellCare's total membership struggles with diabetes every day, as do many of our employees, family members and friends, so awareness, prevention and education are of critical importance to us." The full analyst notes on WellCare Health Plans, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/WCG/report.pdf

--

PDL BioPharma, Inc. Analyst Notes 

On March 13, 2014, PDL BioPharma, Inc. (PDL BioPharma) announced that it has scheduled its annual meeting of stockholders on Wednesday, May 28, 2014, at 10:00 a.m. PT for all stockholders of record on April 4, 2014. The Company informed that the meeting will be held at the Hyatt Regency Hotel in Incline Village, Nevada. The full analyst notes on PDL BioPharma, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/PDLI/report.pdf

--

Lannett Company, Inc. Analyst Notes 

On March 27, 2014, Lannett Company, Inc. (Lannett) announced that Arthur Bedrosian, President and CEO of Lannett, and Martin Galvan, CFO, will present at the 13^th Annual Needham Healthcare Conference on Tuesday, April 8, 2014, at 5:00 p.m. ET at The Westin Grand Central Hotel, in New York. The Company added that an audio webcast of the presentation and its archive for 30 days will be available on its website. The full analyst notes on Lannett Company, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04012014/LCI/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review